The GABA/Diamyd®   trial in the US fully recruited this summer

In the placebo-controlled combination trial GABA/Diamyd® conducted at University of Alabama at Birmingham, US, 82 patients have now been included, of which 48 have completed the entire trial. No serious side effects have been reported and the treatment appears to be safe. The trial is expected to be fully recruited this summer.GABA/Diamyd® is a three-arm, double-blind and placebo-controlled trial including a total of 95 children and adolescents between 4 and 18 years, recently diagnosed with type 1 diabetes. The patients are randomly assigned to one of three treatment groups: a) two